AIMS: Ischemia-reperfusion (I/R) event in vascular and nervous system has been
documented to rising ischemic and vasculitic neuropathic pain, clinically resembles the …

BACKGROUND: Cysteinyl leukotrienes and their receptors have been shown to be involved
in the generation of neuropathic pain. We performed this study to determine the antagonistic …

Background: Various inflammatory mediators are involved in initiating and sustaining
pain/inflammation cascade. Recently, leukotrienes (LTs) have been shown to be important …

Objective The leukotrienes are inflammatory mediators. In the present study, the analgesic
role of local montelukast, a cysteinyl leukotriene receptor antagonist, and the possible …

Despite the availability of many drugs offering symptomatic relief in Parkinson's disease,
there are no drugs available offering neuroprotective effect. Hence, it was decided to …

BACKGROUND: Montelukast is a selective leukotriene D-4 receptor antagonist, which
specifically and reversibly inhibits cysteinyl leukotriene-1 receptor. The aim of this study was …

Cysteinyl leukotrienes (CysLTs) are potent pro-inflammatory and immune modulating lipid
mediators involved in inflammatory diseases and were boosted in human brain after acute …

Background/Aim: Neuropathic pain and neuropathy is commonly seen after ischemia-
reperfusion injuries. Our aim was to evaluate the effect of lutein on ischemia-reperfusion …

Montelukast (MK), a cysteinyl leukotriene (CysLT1) receptor antagonist, latterly exhibited a
remarkable neuroprotective activity in various neurodegenerative disorders. This study aims …

Montelukast Inhibits Pentylenetetrazol-Induced Seizures in Rats - PMC Back to Top Skip to main
content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main …